Second trimester maternal serum screening for down syndrome: Amniocentesis rates and the net number of affected pregnancies identified

Abstract

Traditionally, the efficacy of screening programs has been measured by the sensitivity and false-positive rate and assumes uniform utilization of amniocentesis among all screen-positive women. We evaluated efficacy from the perspective of the actual numbers of amniocenteses performed and Down syndrome (DS) pregnancies prenatally diagnosed.